SODIUM ARSENATE, HEPTAHYDRATE
Names
[ CAS No. ]:
10048-95-0
[ Name ]:
SODIUM ARSENATE, HEPTAHYDRATE
[Synonym ]:
MFCD00149179
disodium,hydrogen arsorate,heptahydrate
EINECS 231-902-4
Chemical & Physical Properties
[ Density]:
1,88 g/cm3
[ Melting Point ]:
180 °C (dec.)(lit.)
[ Molecular Formula ]:
AsH15Na2O11
[ Molecular Weight ]:
312.01400
[ Exact Mass ]:
311.96300
[ PSA ]:
148.03000
[ Stability ]:
Stable. Incompatible with strong reducing agents, strong oxidizing agents, strong acids. Incompatible with iron, aluminium and zinc in the presence of water.
MSDS
Toxicological Information
CHEMICAL IDENTIFICATION
- RTECS NUMBER :
- CG0900000
- CHEMICAL NAME :
- Arsenic acid, disodium salt, heptahydrate
- CAS REGISTRY NUMBER :
- 10048-95-0
- LAST UPDATED :
- 199712
- DATA ITEMS CITED :
- 49
- MOLECULAR FORMULA :
- As-H-O4.2Na.7H2-O
- MOLECULAR WEIGHT :
- 427.00
- WISWESSER LINE NOTATION :
- .NA2.AS-O2-Q2.Q7
HEALTH HAZARD DATA
ACUTE TOXICITY DATA
- TYPE OF TEST :
- LD50 - Lethal dose, 50 percent kill
- ROUTE OF EXPOSURE :
- Intramuscular
- SPECIES OBSERVED :
- Rodent - mouse
- DOSE/DURATION :
- 87360 ug/kg
- TOXIC EFFECTS :
- Details of toxic effects not reported other than lethal dose value
- TYPE OF TEST :
- LDLo - Lowest published lethal dose
- ROUTE OF EXPOSURE :
- Subcutaneous
- SPECIES OBSERVED :
- Rodent - guinea pig
- DOSE/DURATION :
- 50 mg/kg
- TOXIC EFFECTS :
- Behavioral - somnolence (general depressed activity) Behavioral - convulsions or effect on seizure threshold Behavioral - ataxia
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Oral
- SPECIES OBSERVED :
- Rodent - mouse
- DOSE/DURATION :
- 43 mg/kg/4W-C
- TOXIC EFFECTS :
- Liver - other changes Endocrine - hypoglycemia Blood - changes in serum composition (e.g. TP, bilirubin, cholesterol)
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Intraperitoneal
- DOSE :
- 30 mg/kg
- SEX/DURATION :
- female 9 day(s) after conception
- TOXIC EFFECTS :
- Reproductive - Fertility - post-implantation mortality (e.g. dead and/or resorbed implants per total number of implants) Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death, e.g., stunted fetus)
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Intraperitoneal
- DOSE :
- 20 mg/kg
- SEX/DURATION :
- female 9 day(s) after conception
- TOXIC EFFECTS :
- Reproductive - Specific Developmental Abnormalities - eye/ear Reproductive - Specific Developmental Abnormalities - Central Nervous System
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Intraperitoneal
- DOSE :
- 20 mg/kg
- SEX/DURATION :
- female 10 day(s) after conception
- TOXIC EFFECTS :
- Reproductive - Specific Developmental Abnormalities - musculoskeletal system Reproductive - Specific Developmental Abnormalities - urogenital system
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Oral
- DOSE :
- 120 mg/kg
- SEX/DURATION :
- female 10 day(s) after conception
- TOXIC EFFECTS :
- Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death, e.g., stunted fetus)
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Oral
- DOSE :
- 120 mg/kg
- SEX/DURATION :
- female 10 day(s) after conception
- TOXIC EFFECTS :
- Reproductive - Fertility - post-implantation mortality (e.g. dead and/or resorbed implants per total number of implants) Reproductive - Effects on Embryo or Fetus - fetal death
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Intraperitoneal
- DOSE :
- 40 mg/kg
- SEX/DURATION :
- female 9 day(s) after conception
- TOXIC EFFECTS :
- Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death, e.g., stunted fetus) Reproductive - Specific Developmental Abnormalities - musculoskeletal system Reproductive - Specific Developmental Abnormalities - other developmental abnormalities
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Intraperitoneal
- DOSE :
- 40 mg/kg
- SEX/DURATION :
- female 9 day(s) after conception
- TOXIC EFFECTS :
- Reproductive - Specific Developmental Abnormalities - Central Nervous System Reproductive - Specific Developmental Abnormalities - eye/ear Reproductive - Specific Developmental Abnormalities - craniofacial (including nose and tongue)
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Intraperitoneal
- DOSE :
- 40 mg/kg
- SEX/DURATION :
- female 9 day(s) after conception
- TOXIC EFFECTS :
- Reproductive - Fertility - post-implantation mortality (e.g. dead and/or resorbed implants per total number of implants) Reproductive - Effects on Embryo or Fetus - fetal death Reproductive - Specific Developmental Abnormalities - body wall
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Intraperitoneal
- DOSE :
- 45 mg/kg
- SEX/DURATION :
- female 9 day(s) after conception
- TOXIC EFFECTS :
- Reproductive - Fertility - litter size (e.g. # fetuses per litter; measured before birth)
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Intraperitoneal
- DOSE :
- 20 mg/kg
- SEX/DURATION :
- female 8 day(s) after conception
- TOXIC EFFECTS :
- Reproductive - Effects on Embryo or Fetus - fetal death Reproductive - Specific Developmental Abnormalities - craniofacial (including nose and tongue)
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Intravenous
- DOSE :
- 15 mg/kg
- SEX/DURATION :
- female 8 day(s) after conception
- TOXIC EFFECTS :
- Reproductive - Fertility - post-implantation mortality (e.g. dead and/or resorbed implants per total number of implants) Reproductive - Specific Developmental Abnormalities - musculoskeletal system Reproductive - Specific Developmental Abnormalities - urogenital system
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Intravenous
- DOSE :
- 15 mg/kg
- SEX/DURATION :
- female 8 day(s) after conception
- TOXIC EFFECTS :
- Reproductive - Specific Developmental Abnormalities - craniofacial (including nose and tongue) Reproductive - Specific Developmental Abnormalities - eye/ear
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Intravenous
- DOSE :
- 20 mg/kg
- SEX/DURATION :
- female 8 day(s) after conception
- TOXIC EFFECTS :
- Reproductive - Specific Developmental Abnormalities - Central Nervous System
- TYPE OF TEST :
- Cytogenetic analysis
MUTATION DATA
- TYPE OF TEST :
- Sister chromatid exchange
- TEST SYSTEM :
- Rodent - hamster Fibroblast
- REFERENCE :
- MUREAV Mutation Research. (Elsevier Science Pub. B.V., POB 211, 1000 AE Amsterdam, Netherlands) V.1- 1964- Volume(issue)/page/year: 104,141,1982 *** REVIEWS *** ACGIH TLV-TWA 0.01 mg(As)/m3 DTLVS* The Threshold Limit Values (TLVs) and Biological Exposure Indices (BEIs) booklet issues by American Conference of Governmental Industrial Hygienists (ACGIH), Cincinnati, OH, 1996 Volume(issue)/page/year: TLV/BEI,1997 ACGIH TLV-Confirmed human carcinogen DTLVS* The Threshold Limit Values (TLVs) and Biological Exposure Indices (BEIs) booklet issues by American Conference of Governmental Industrial Hygienists (ACGIH), Cincinnati, OH, 1996 Volume(issue)/page/year: TLV/BEI,1997 *** U.S. STANDARDS AND REGULATIONS *** MSHA STANDARD-air:TWA 0.5 mg(As)/m3 DTLVS* The Threshold Limit Values (TLVs) and Biological Exposure Indices (BEIs) booklet issues by American Conference of Governmental Industrial Hygienists (ACGIH), Cincinnati, OH, 1996 Volume(issue)/page/year: 3,16,1971 OSHA-cancer hazard CFRGBR Code of Federal Regulations. (U.S. Government Printing Office, Supt. of Documents, Washington, DC 20402) Volume(issue)/page/year: 29,1910.1018,1987 *** OCCUPATIONAL EXPOSURE LIMITS *** OEL-ARAB Republic of Egypt:TWA 0.2 mg(As)/m3 JAN 1993 OEL-AUSTRALIA:TWA 0.05 mg(As)/m3;Carcinogen JAN 1993 OEL-BELGIUM:TWA 0.2 mg(As)/m3 JAN 1993 OEL-DENMARK:TWA 0.05 mg(As)/m3 JAN 1993 OEL-FINLAND;Carcinogen JAN 1993 OEL-FRANCE:TWA 0.2 mg(As)/m3 JAN 1993 OEL-HUNGARY:STEL 0.5 mg(As)/m3;Carcinogen JAN 1993 OEL-INDIA:TWA 0.2 mg(As)/m3 JAN 1993 OEL-THE PHILIPPINES:TWA 0.5 mg(As)/m3 JAN 1993 OEL-POLAND:TWA 0.3 mg(As)/m3 JAN 1993 OEL-SWEDEN:TWA 0.03 mg(As)/m3;Carcinogen JAN 1993 OEL-SWITZERLAND:TWA 0.1 mg(As)/m3;Carcinogen JAN 1993 OEL-THAILAND:TWA 0.5 mg(As)/m3 JAN 1993 OEL-TURKEY:TWA 0.5 mg(As)/m3 JAN 1993 OEL-UNITED KINGDOM:TWA 0.2 mg(As)/m3 JAN 1993 OEL IN BULGARIA, COLOMBIA, JORDAN, KOREA check ACGIH TLV OEL IN NEW ZEALAND, SINGAPORE, VIETNAM check ACGIH TLV *** NIOSH STANDARDS DEVELOPMENT AND SURVEILLANCE DATA *** NIOSH RECOMMENDED EXPOSURE LEVEL (REL) : NIOSH REL TO ARSENIC, INORGANIC-air:CA CL 0.002 mg(As)/m3/15M REFERENCE : NIOSH* National Institute for Occupational Safety and Health, U.S. Dept. of Health, Education, and Welfare, Reports and Memoranda. Volume(issue)/page/year: DHHS #92-100,1992
Safety Information
[ Symbol ]:
GHS06, GHS08, GHS09
[ Signal Word ]:
Danger
[ Hazard Statements ]:
H301 + H331-H350-H410
[ Precautionary Statements ]:
P201-P261-P273-P301 + P310-P311-P501
[ Personal Protective Equipment ]:
Eyeshields;Faceshields;full-face particle respirator type N100 (US);Gloves;respirator cartridge type N100 (US);type P1 (EN143) respirator filter;type P3 (EN 143) respirator cartridges
[ Hazard Codes ]:
T,N
[ Risk Phrases ]:
45-23/25-50/53
[ Safety Phrases ]:
S53-S45-S60-S61
[ RIDADR ]:
UN 1685 6.1/PG 2
[ WGK Germany ]:
3
[ RTECS ]:
CG0900000
[ Packaging Group ]:
II
[ Hazard Class ]:
6.1
Articles
J. Toxicol. Environ. Health A 76(7) , 458-78, (2013)
This report summarizes the results of a study to develop an in vitro bioaccessibility (IVBA) extraction technique for estimating the relative bioavailability (RBA) of arsenic (As) in soil. The study w...
J. Toxicol. Environ. Health A 76(7) , 449-57, (2013)
This study describes a method for measuring the relative oral bioavailability (RBA) of arsenic (As) in soil and other soil-like media using young swine as the animal model. Groups of animals are expos...
Comp. Biochem. Physiol. C. Toxicol. Pharmacol. 155(4) , 566-72, (2012)
Arsenic (As) exposure has been associated with serious chronic health risk to humans including cancer and neurological disturbances. However, there are limited studies about the mechanisms behind its ...